MEDIA RELEASE
Cheyenne, WY, June 12, 2024 – AxonDAO (Axon DAO LLC, Wyoming) is thrilled to introduce A+Voice, a cutting-edge research platform created to monitor vocal biomarkers. This platform serves as a highly effective tool for the early detection and continuous assessment of conditions like Alzheimer’s, Parkinson’s, dementia, post-traumatic stress disorder (PTSD), and Huntington’s Disease.
The evaluation of vocal biomarkers can also help determine fatigue and energy levels, potentially revolutionizing safety monitoring across various professions, including commercial truck drivers, car operators, and heavy machinery workers. In the future, AxonDAO aims to enhance their models to identify biomarkers that assess changes in anxiety, stress, and mood.
Utilizing decentralized ledger technology, zero-knowledge security, and other advanced tools, AxonDAO empowers research participants to access, own, and manage their health data. Through community involvement and transparent data gathering, AxonDAO enables research studies on a larger scale than traditional methods, whether conducted by academia or industry.
Introducing A+Voice
A+Voice is AxonDAO’s groundbreaking biometric AI voice collection and analysis software. The platform employs a reward system to gather high-quality voice data consistently, which is then processed through a quality assessment and analytical engine. With the use of blockchain technology, A+Voice timestamps, anonymizes, and analyzes this data into patterned AI processes while complying with strict HIPAA and ISO 27001 standards for secure data handling.
Strategic Partnerships and Achievements
AxonDAO’s recent approval for NVIDIA’s Inception Program on October 27, 2023, underscores its commitment to excellence. In March, the AxonDAO team presented its vision at NVIDIA’s GTC event in San Jose, California. Strategic collaborations have supported the launch of A+Voice:
NVIDIA: Enabling the scalability of A+Voice and products through state-of-the-art GPU processors.
639 Solar: Hosting AxonDAO’s DeSci Research Toolkit and Computational Engine in one of the world’s largest solar-powered data centers.
DataLake: Providing industry-leading consent management standards, including user rights to withdraw personal data access.
AxonDAO’s Vision and Market Potential
AxonDAO is dedicated to fostering human connections and advancing scientific research through biometric data. The personal data market, currently valued at $1.61 trillion, is projected to reach $17.06 trillion by 2029 with the integration of high-quality biometric data.
AxonDAO on Mario’s Nawfal Roundtable X Account
AxonDAO will be featured on Mario’s Roundtable X account this Thursday, June 13th, at 12:00 PM EST. Join the session to discover more about AxonDAO’s groundbreaking work and its vision for the future of decentralized science.
About $AXGT
AxonDAO’s governance token, $AXGT, is an Ethereum-based token with connections to Arbitrum and BASE. $AXGT is undergoing a security audit by Certik. The token is available on UniSwap and will be submitted for listing on major Tier 1 exchanges for easier access. $AXGT’s utility includes voting on projects to be funded, submitting projects, and participating in data collection within the AxonDAO ecosystem. The current market cap is $44.7M, with a fully diluted valuation (FDV) of $271M, and is currently priced at $0.271 per $AXGT.
For further information, visit axondao.io.
About AxonDAO
AxonDAO is a decentralized autonomous organization focused on constructing, financing, and supporting scientific research using biometric data. By leveraging blockchain and AI technologies, AxonDAO aims to transform how biometric data is gathered, processed, and utilized for scientific progress.
Media Contact:
[email protected]
[email protected]
This communication is a press release. Readers are advised to conduct their own research before taking any actions related to the promoted company or any of its affiliates or services. Bitcoin.com bears no responsibility, directly or indirectly, for any harm or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods, or services mentioned in the press release.
